Abiraterone Acetate Plus Prednisone Provided Significant Clinical Benefit in Patients with High-Risk Metastatic Hormone-Naïve Prostate Cancer (mHNPC), Improving Overall Survival and Radiographic Progression-Free Survival
Beerse, Belgium, 3 June, 2017 – Janssen-Cilag International NV today announced data from the pivotal Phase 3 LATITUDE clinical trial, which showed Zytiga…